CA2506719A1 - Treatment of chronic heart failure - Google Patents
Treatment of chronic heart failure Download PDFInfo
- Publication number
- CA2506719A1 CA2506719A1 CA002506719A CA2506719A CA2506719A1 CA 2506719 A1 CA2506719 A1 CA 2506719A1 CA 002506719 A CA002506719 A CA 002506719A CA 2506719 A CA2506719 A CA 2506719A CA 2506719 A1 CA2506719 A1 CA 2506719A1
- Authority
- CA
- Canada
- Prior art keywords
- group
- substituted
- alkyl
- chf
- unsubstituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/325,420 US20040122067A1 (en) | 2002-12-20 | 2002-12-20 | Treatment of chronic heart failure |
| US10/325,420 | 2002-12-20 | ||
| PCT/US2003/039410 WO2004060489A2 (en) | 2002-12-20 | 2003-12-11 | Treatment of chronic heart failure |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2506719A1 true CA2506719A1 (en) | 2004-07-22 |
Family
ID=32593758
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002506719A Abandoned CA2506719A1 (en) | 2002-12-20 | 2003-12-11 | Treatment of chronic heart failure |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20040122067A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1581308A2 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2006514051A (cg-RX-API-DMAC7.html) |
| CA (1) | CA2506719A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MXPA05006628A (cg-RX-API-DMAC7.html) |
| PL (1) | PL375893A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2004060489A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005027887A2 (en) * | 2003-09-17 | 2005-03-31 | Cardimone Pharma Corporation | Methods and compositions for improving endothelial function |
| WO2006121995A2 (en) * | 2005-05-09 | 2006-11-16 | Tap Pharmaceutical Products, Inc. | Methods for treating nephrolithiasis |
| CA2669935A1 (en) * | 2006-11-13 | 2008-05-29 | Takeda Pharmaceuticals North America, Inc. | Methods for preserving renal function using xanthine oxidoreductase inhibitors |
| US20090124623A1 (en) * | 2006-11-13 | 2009-05-14 | Christopher Lademacher | Methods for preserving and/or increasing renal function using xanthine oxidoreductase inhibitors |
| RU2009131454A (ru) * | 2007-01-19 | 2011-02-27 | Такеда Фармасьютикалз Норт Америка, Инк. (Us) | Способы предупреждения или уменьшения числа обострений подагры с применением ингибиторов ксантиноксидоредуктазы и противовоспалительных средств |
| US20100311756A1 (en) * | 2009-01-22 | 2010-12-09 | Takeda Pharmaceuticals North America, Inc. | Methods for delaying the progression of at least one of cardiac hypertrophy, cardiac remodeling or left ventricular function or the onset of heart failure in subjects in need of treatment thereof |
| GB0909243D0 (en) * | 2009-05-29 | 2009-07-15 | Univ Dundee | Angina treatment |
| IT1400309B1 (it) | 2010-05-10 | 2013-05-24 | Menarini Int Operations Lu Sa | Associazione di inibitori della xantina ossidasi e calcio antagonisti e loro uso. |
| IT1400609B1 (it) | 2010-05-10 | 2013-06-14 | Menarini Int Operations Lu Sa | Associazione di inibitori della xantina ossidasi e metformina e loro uso. |
| IT1400311B1 (it) | 2010-05-10 | 2013-05-24 | Menarini Int Operations Lu Sa | Associazione di inibitori della xantina ossidasi e antagonisti del recettore dell'angiotensina ii e loro uso. |
| IT1400310B1 (it) | 2010-05-10 | 2013-05-24 | Menarini Int Operations Lu Sa | Associazione di inibitori della xantina ossidasi e statine e loro uso. |
| JP5978216B2 (ja) | 2010-09-10 | 2016-08-24 | タケダ ファーマシューティカルズ ユー.エス.エー. インコーポレイティド | テオフィリンとフェブキソスタットの併用療法のための方法 |
| US20170217948A1 (en) | 2014-07-30 | 2017-08-03 | Teijin Pharma Limited | Xanthine oxidase inhibitor |
| JP6684264B2 (ja) * | 2015-02-17 | 2020-04-22 | 株式会社三和化学研究所 | 心不全の予防又は治療のための医薬 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2073981C (en) * | 1990-11-30 | 2002-01-08 | Shiro Kondo | 2-arylthiazole derivatives and pharmaceutical composition thereof |
| AU1520699A (en) * | 1997-11-07 | 1999-05-31 | Johns Hopkins University, The | Methods for treatment of disorders of cardiac contractility |
| CZ297264B6 (cs) * | 1998-09-09 | 2006-10-11 | Metabasis Therapeutics, Inc. | Nové heteroaromatické inhibitory fruktóza-1,6-bisfosfatázy |
| DE69942009D1 (de) * | 1998-10-15 | 2010-03-25 | Imp Innovations Ltd | Verbindungen für die behandlung von gewichtsverlust |
| EP1212064A2 (en) * | 1999-03-09 | 2002-06-12 | Max-Delbrück-Centrum Für Molekulare Medizin | Use of inhibitors of endotoxin for the treatment of heart failure and of cachexia |
-
2002
- 2002-12-20 US US10/325,420 patent/US20040122067A1/en not_active Abandoned
-
2003
- 2003-12-11 CA CA002506719A patent/CA2506719A1/en not_active Abandoned
- 2003-12-11 EP EP03796950A patent/EP1581308A2/en not_active Withdrawn
- 2003-12-11 JP JP2004565376A patent/JP2006514051A/ja active Pending
- 2003-12-11 MX MXPA05006628A patent/MXPA05006628A/es unknown
- 2003-12-11 PL PL03375893A patent/PL375893A1/xx unknown
- 2003-12-11 WO PCT/US2003/039410 patent/WO2004060489A2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| MXPA05006628A (es) | 2005-09-30 |
| WO2004060489A3 (en) | 2004-11-25 |
| JP2006514051A (ja) | 2006-04-27 |
| EP1581308A2 (en) | 2005-10-05 |
| PL375893A1 (en) | 2005-12-12 |
| WO2004060489A2 (en) | 2004-07-22 |
| US20040122067A1 (en) | 2004-06-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6584391B2 (ja) | 非ホジキンリンパ腫を治療するための、hdac阻害剤単独またはpi3k阻害剤との組み合わせ | |
| EP2814486B1 (en) | Antiviral drugs for treatment of arenavirus infection | |
| US7872037B2 (en) | Antiviral drugs for treatment of arenavirus infection | |
| EP3076973B1 (en) | Combinations of histone deacetylase inhibitors and immunomodulatory drugs | |
| EP2182805B1 (en) | Antiviral drugs for treatment of arenavirus infection | |
| US20040122067A1 (en) | Treatment of chronic heart failure | |
| AU2006327892B2 (en) | Histone deacetylase inhibitors for enhancing activity of antifungal agents | |
| MX2009007680A (es) | Metodos para prevenir o reducir el numero de expansiones graduales de gota utilizando inhibidores de oxidoreductasa de xantina y agentes anti-inflamatorios. | |
| WO2015054197A1 (en) | Hdac inhibitors, alone or in combination with btk inhibitors, for treating non-hodgkin's lymphoma | |
| JP2022121599A (ja) | 慢性リンパ性白血病の治療を目的とするhdac阻害剤単独またはbtk阻害剤との配合物 | |
| CN101466435A (zh) | Kw-3902在充血性心脏衰竭和急性体液超负荷患者中实现利尿作用的用途 | |
| CN101420958A (zh) | 共投与腺苷a1受体拮抗剂和抗惊厥药 | |
| EP3068400A1 (en) | Methods for reducing uric acid levels using barbiturate derivatives | |
| US20060252808A1 (en) | Methods for treating nephrolithiasis | |
| US20040254228A1 (en) | Treatment of chronic heart failure | |
| CA2808492A1 (en) | Antifungal agents and uses thereof | |
| KR20000005115A (ko) | 이미다졸유도체를함유하는함유하는항-hiv조성물 | |
| JPWO2003047591A1 (ja) | 肺高血圧症予防治療剤 | |
| EP1948183B1 (en) | Compositions for the treatment and prevention of heart disease and methods of using same | |
| US8871746B2 (en) | Antiviral drugs for treatment of arenavirus infection | |
| US20200016168A1 (en) | Compositions and methods for reactivating latent hiv-1 infections | |
| Lahlou et al. | Dose-dependent therapeutic effects of trans-3-methoxy-β-nitrostyrene in rat model of monocrotaline-induced pulmonary hypertension | |
| HUP0402593A2 (hu) | Kariporidból és ramiprilből álló kombinációs készítmény és alkalmazása | |
| WO1988007368A2 (fr) | Composition medicamenteuse pour le traitement et la prevention de maladies dues a une cytotoxicite a mediation cellulaire, renfermant au moins un derive de la pyridine comme principe actif | |
| HK1204949B (en) | Antiviral drugs for treatment of arenavirus infection |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |